logo
episode-header-image
Jul 2024
18m 1s

Developments in CAR T-cell Therapy

European Hematology Association
About this episode
tail spinning
Up next
Sep 6
Life After YERM: How the Young EHA Research Meeting Shaped Careers
In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear ... Show More
21m 5s
Sep 6
Discover YERM: The Young EHA Research Meeting and Your Place in It
Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to em ... Show More
19m 28s
Aug 28
CAR-T for Pediatric B-ALL: Expert Tips
In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move ea ... Show More
21m 34s
Recommended Episodes
Aug 2022
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provid ... Show More
1h 30m
Nov 2024
CAR T Cells and T-Cell Therapies for Cancer
<p>CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott ... Show More
18m 22s
Jun 2025
Reprogramming Immunity: Unlocking CAR-NK Cells with Dr. Hind Rafei
<p>In this episode, Dr. Hind Rafei dives into the cutting-edge world of CAR-NK cell therapy and its potential to revolutionize cancer treatment. Unlike their T-cell counterparts, CAR-NK cells promise enhanced safety and innate tumor-killing ability. But what if their power could ... Show More
26m 51s
Jun 2022
#342 Checkpoint Inhibitors: The power, and adverse effects, of immunotherapy (ACP 2022)
With great power comes great immunogenicity. Learn about the ins and outs of immunotherapy–its indications, its power, and its adverse effects–in this episode with Dr. Christian Cable, hematologist/oncologist and medical educator extraordinaire. We learn a riveting history of imm ... Show More
54m 36s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
Dec 2024
263. Cytokines Everywhere All at Once: Approach to CRS and ICANS
Send us Fan MailAs a result of the rapid adoption CAR-T therapy for certain lymphoid malignancies and multiple myeloma, of these treatments, CRS and ICANS will become more common in IM wards in the coming years. Take a listen to learn about how to treat this emerging condition. T ... Show More
17m 17s
Apr 2024
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
tail spinning
19m 57s
Oct 2025
Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms
In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a b ... Show More
24m 11s
Jun 2024
EHA2024 Chronic Lymphocytic Leukemia Preview: The Road Ahead With Targeted Therapies
Join the experts for an in-depth discussion on the latest developments in targeted therapies for relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and a look ahead to the upcoming EHA2024 conference. Credit available for this activity expires: 6/6/2025 Earn Credit / Lea ... Show More
33m 47s
Mar 2024
Innovations in CAR T-Cell Therapy for Multiple Myeloma
<p><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. John Sweetenham and Shaji Kumar discuss the emergence of CAR T-cell therapy for multiple myeloma, its benefits and challenges for patients, and its potential role earlier in the treatment of diseas ... Show More
20m 55s